A Phase III Open-label, Multicenter Trial of Avelumab (MSB0010718C) as a Third-line Treatment of Unresectable, Recurrent, or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Trial Profile

A Phase III Open-label, Multicenter Trial of Avelumab (MSB0010718C) as a Third-line Treatment of Unresectable, Recurrent, or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 28 Nov 2017

At a glance

  • Drugs Avelumab (Primary) ; Irinotecan; Paclitaxel
  • Indications Adenocarcinoma; Gastric cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms JAVELIN Gastric 300
  • Sponsors EMD Serono
  • Most Recent Events

    • 28 Nov 2017 Results published in a Pfizer media release.
    • 28 Nov 2017 According to a Pfizer media release, results will be submitted for presentation at an upcoming medical congress.
    • 28 Nov 2017 Primary endpoint has not been met. (Overall Survival), as reported in a Pfizer media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top